Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy

Diabetic Nephropathy Clinical Trial

Official title:

A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01743014
• Other study ID #: 15/10-7-2012
• Status: Recruiting
• Phase: Phase 4
• First received: November 21, 2012
• Last updated: December 4, 2012
• Start date: July 2012
• Est. completion date: July 2015

Study information

• Verified date: November 2012
• Source: AHEPA University Hospital
• Contact: Fotios S Iliadis, Lecturer of Internal Medicine
• Phone: +306974960728
• Email: iliadis[@]med.auth.gr
• Is FDA regulated: No
• Health authority: Greece: Aristotle University of Thessaloniki
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the combination with ramipril and clopidogrel leads to further improvement of endothelial function, reduction of oxidative stress and reduction of vascular inflammation, compared with ramipril monotherapy, in patients with Diabetes Mellitus type 2 and diabetic nephropathy.

Description:

• Cardiovascular disease is the leading cause of deaths in diabetic population with diabetic nephropathy.

• Pharmacologic therapy for patients with diabetes and hypertension should be with a regimen that includes either an angiotensin-converting-enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB)

• Diabetic patients at increased cardiovascular risk should receive an antiplatelet agent for primary prevention.

Methods:

An open label,randomized, two period cross-over design study, involving patients with type 2 diabetes and diabetic nephropathy. After a 4 weeks wash out period for ACE inhibitors or Angiotensin receptor blockers (week 0, baseline) 60 patients will be randomized to receive ramipril(10 mg) only or ramipril (10 mg) and clopidogrel (75mg) for 12 weeks exchanging their treatment for a further 12 weeks, after a 2 week wash out period for clopidogrel. Patients will be examined and measurements will be taken at baseline (week 0), and at the end of 12, 14, and 26 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: July 2015
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria: type 2 diabetes patients with diabetic nephropathy in the range of micro- or macroalbuminuria and

• HbA1c(glycosylated haemoglobin A1c <7%

• Blood pressure =130/80 mmHg

• LDL (Low Density Lipoproteins) <100 mg/dl

• Informed consent

Exclusion Criteria:

• patients with diabetic nephropathy and estimated GFR <30ml/min with Modification of Diet in Renal Disease equation (MDRD equation)

• baseline potassium > 5.2 meq/L

• patients with nephrotic proteinuria defined as albumine to creatinine ratio (ACR)> 3.5 g/g or as proteinuria >3.5 g per 1.73 m2 per 24 hours

• history or evidence of non-diabetic kidney disease

• history of stroke, peripheral artery disease, coronary artery disease

• history or evidence of a secondary form of hypertension

• history of severe hepatic failure, malignancy, severe endocrinopathy,autoimmune disease or chronic inflammatory disease

• any known bleeding or platelet disorder or platelets <100.000/µL

• heart failure in New York Heart Association(NYHA) functional class II-IV

• inability or unwillingness on the part of the patient to sign the Patient Consent Form

• known hypersensitivity to ramipril or to clopidogrel

• Women of child-bearing potential

• use of oral anticoagulants or other antithrombotic treatment

• use of glitazones

• patients receiving statins should be on a stable dose of at least 3 months prior to study initiation and dose should be constant during the study

• any surgical or medical condition which in the opinion of the investigator may expose the patient to a higher risk in participation in the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Diabetes Type 2
• Diabetic Nephropathies
• Diabetic Nephropathy
• Inflammation
• Kidney Diseases
• Vascular Disease
• Vascular Diseases

Intervention

Drug:
• Ramipril
Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
• Clopidogrel
12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.

Locations

Country	Name	City	State
Greece	AHEPA University Hospital	Thessaloniki
Greece	Aristotle University of Thessaloniki/ AHEPA University Hospital	Thessaloniki

Sponsors (2)

Lead Sponsor	Collaborator
AHEPA University Hospital	Aristotle University Of Thessaloniki

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Asymmetric dimethylarginine (ADMA) blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy	The primary aim is to investigate the effect of the combined treatment with ramipril and clopidogrel versus ramipril monotherapy in ADMA as biomarker of endothelial dysfunction.	Baseline to week 12 and week 14 to week 26	No
Primary	Changes in High-sensitivity C-reactive protein (HsCRP) blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy	The primary aim is to investigate the effect of the combined treatment with ramipril and clopidogrel versus ramipril monotherapy in hsCRP as biomarker of vascular inflammation	Baseline to week 12 and week 14 to week 26	No
Primary	Changes in soluble CD40 Ligand (sCD40L)blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy	The primary aim is to investigate the effect of the combined treatment with ramipril and clopidogrel versus ramipril monotherapy in soluble CD40 Ligand as biomarker of vascular inflammation.	Baseline to week 12 and week 14 to week 26	No
Primary	Changes in urine 8-isoprostane-F2 levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy	The primary aim is to investigate the effect of the combined treatment with ramipril and clopidogrel versus ramipril monotherapy in urine 8-isoprostane-F2 as biomarker of oxidative stress.	Baseline to week 12 and week 14 to week 26	No
Primary	Reduction in albumine to creatine ratio after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy	The primary aim is to investigate the effect of the combined treatment with ramipril and clopidogrel versus ramipril monotherapy in albumine to creatine ratio as an index of cardiovascular disease	Baseline to week 12 and week 14 to week 26	No
Secondary	Changes in ADMA blood levels after treatment with ramipril	Evaluation of the effect of ramipril, as antihypertensive therapy, in endothelial dysfunction in patients with diabetes mellitus type 2 and diabetic nephropathy	baseline to week 26	No
Secondary	Increase of Glomerular Filtration Rate (GFR) after combined treatment with ramipril and clopidogrel and after ramipril monotherapy		baseline to week 12 and week 14 to week 26	No
Secondary	Change from baseline in carotid intima-media thickness after combined therapy with ramipril and clopidogrel and after ramipril monotherapy		baselibe to week 12 and week 14 to week 26	No